CN102040596A - Dasatinib polymorph and preparation method thereof - Google Patents

Dasatinib polymorph and preparation method thereof Download PDF

Info

Publication number
CN102040596A
CN102040596A CN2009101969878A CN200910196987A CN102040596A CN 102040596 A CN102040596 A CN 102040596A CN 2009101969878 A CN2009101969878 A CN 2009101969878A CN 200910196987 A CN200910196987 A CN 200910196987A CN 102040596 A CN102040596 A CN 102040596A
Authority
CN
China
Prior art keywords
dasatinib
type
polymorphic
illustrative plates
collection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009101969878A
Other languages
Chinese (zh)
Inventor
刘蔚
蔡志刚
王锰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI XIDI PHARMACEUTICAL CO Ltd
Original Assignee
SHANGHAI XIDI PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI XIDI PHARMACEUTICAL CO Ltd filed Critical SHANGHAI XIDI PHARMACEUTICAL CO Ltd
Priority to CN2009101969878A priority Critical patent/CN102040596A/en
Publication of CN102040596A publication Critical patent/CN102040596A/en
Pending legal-status Critical Current

Links

Abstract

The invention discloses a dasatinib polymorph and a preparation method thereof. The invention is characterized in that: a powder diffraction pattern of the crystal comprises three or more than three 2theta values of 7.2 degrees, 10.6 degrees, 12.2 degrees, 14.5 degrees, 16.4 degrees, 20.0 degrees, 22.8 degrees and 23.7+/-0.2 degrees. In addition, the invention also discloses a method for preparing the dasatinib polymorph. The dasatinib polymorph is easy for industrial production and is a novel pharmaceutically acceptable and stable dasatinib polymorph.

Description

Dasatinib polymorph and preparation method thereof
Technical field
The present invention relates to Dasatinib polymorph and preparation method thereof.
Background technology
Dasatinib (Dasatinib), commodity are called Sprycel, are a kind of oral tyrosine kinase inhibitors by Bristol-Myers Squibb Co.'s research and development.This medicine is in the June 28 in 2006 of preferentially examining by U.S. FDA, be used for all stadium patients, also be used for the treatment of simultaneously other therapy resistances or the Philadelphia chromosome male acute lymphoblastic leukemia adult patient (ph+ALL) that do not tolerate to treatment failure previously or adult's chronic myelogenous leukemia (CML) of not tolerating.
Dasatinib has the disclosed monohydrate H1-7 of CN1980909A crystal formation, propyl carbinol solvate BU-2 crystal formation, alcohol solvent compound E2-1 crystal formation, pure product N-6 crystal formation and pure product T1N1-7 crystal formation at present, the crystallized form of the various salt of the disclosed Dasatinib of WO2007035874 (such as mesylate, hydrobromate, salicylate etc.), and WO2009053854 discloses the multiple crystal formation (comprising isopropanol solvent compound, Virahol-crystal formations such as dimethylsulfoxide solvent compound) of Dasatinib.
Summary of the invention
The object of the present invention is to provide a kind of Dasatinib polymorph and preparation method thereof, to overcome the above-mentioned defective that prior art exists.
Dasatinib polymorph of the present invention is the crystal formation of pure product form, is designated as the I type;
Further, described Dasatinib polymorph is characterised in that, the powder diffraction spectrum of this polymorphic form comprises and is selected from following 2 θ values more than 3 or 3: 7.2 °, and 10.6 °, 12.2 °, 14.5 °, 16.4 °, 20.0 °, 22.8 °, 23.7 ± 0.2 °; Dsc (DSC) is analyzed collection of illustrative plates has the feature endotherm(ic)peak at about 285~287 ℃; Thermogravimetric analysis (TGA) collection of illustrative plates is weightless about below 1%.
The preparation method of the Dasatinib polymorph that the present invention is above-mentioned comprises the steps:
With raw material Dasatinib under 30~70 ℃ of conditions dry 1~8 hour, remove solvent, can obtain the Dasatinib of I type;
Said raw material Dasatinib is selected from more than one in II type Dasatinib polymorph, III type Dasatinib polymorph or the IV type Dasatinib polymorph;
Described Dasatinib II type polymorphic form for dichloromethane solvent compound crystal formation, is characterized in that, the powder diffraction spectrum of this polymorphic form comprises and is selected from following 2 θ values more than 4 or 4: 5.9 °, 11.8 °, 12.4 °, 14.8 °, 17.7 °, 18.6 °, 21.6 °, 22.9 °, 23.7 °, 25.4 ± 0.2 °; The DSC collection of illustrative plates has the feature endotherm(ic)peak at about 80~160 ℃ and 285~287 ℃; The TGA collection of illustrative plates shows weightless about 14%.
The preparation method of the Dasatinib II type polymorphic form that the present invention is above-mentioned comprises the steps:
1) the crude product Dasatinib is suspended in the methylene dichloride, 20~40 ℃ were stirred 0.5~1 hour down;
2) filter, the filter cake washed with dichloromethane promptly obtains II type Dasatinib.
3) or with Dasatinib be dissolved in the aqueous organic solvent, obtain Dasatinib solution.
4) this drips of solution is added in the methylene dichloride.
5) filter, promptly obtain II type Dasatinib.
Described aqueous organic solvent is selected from methyl alcohol, ethanol, 1-propyl alcohol, 2-propyl alcohol, tetrahydrofuran (THF), ethylene glycol, methyl-sulphoxide, N, dinethylformamide and their mixture thereof, preferred methyl-sulphoxide.
The Dasatinib III type polymorphic form that the present invention is above-mentioned, be isopropyl ether solvate crystal formation, it is characterized in that the powder diffraction spectrum of this polymorphic form comprises and is selected from following 2 θ values more than 4 or 4: 5.9 °, 11.9 °, 15.0 °, 16.6 °, 21.5 °, 22.9 °, 24.0 °, 24.5 ± 0.2 °; The DSC collection of illustrative plates has the feature endotherm(ic)peak at about 110~160 ℃ and 285~288 ℃; TGA shows collection of illustrative plates weightless about 13%.
The preparation method of the Dasatinib III type polymorphic form that the present invention is above-mentioned comprises the steps:
1) the crude product Dasatinib is suspended in the isopropyl ether, 30~70 ℃ were stirred 0.5~1 hour down.
2) filter, promptly obtain II type Dasatinib.
3) or with Dasatinib be dissolved in the aqueous organic solvent, obtain Dasatinib solution.
4) this drips of solution is added in the isopropyl ether.
5) filter, promptly obtain II type Dasatinib.
The aqueous organic solvent definition is the same.
The Dasatinib IV type polymorphic form that the present invention is above-mentioned is N, dinethylformamide solvate crystal formation, it is characterized in that, the powder diffraction spectrum of this polymorphic form comprises and is selected from following 2 θ values more than 4 or 4: 5.5 °, and 5.9 °, 12.4 °, 14.8 °, 16.5 °, 22.2 °, 22.8 °, 24.8 °, 25.4 ± 0.2 °; The DSC collection of illustrative plates has the feature endotherm(ic)peak at about 115~139 ℃ and 285~287 ℃; TGA shows collection of illustrative plates weightless about 8.67%.
The preparation method of the Dasatinib IV type polymorphic form that the present invention is above-mentioned comprises the steps:
1) the crude product Dasatinib is suspended in N, in the dinethylformamide, 40~90 ℃ were stirred 0.5~1 hour down.
2) with the speed of per hour the falling 10 ℃ crystallization of slowly lowering the temperature.Filter, promptly obtain II type Dasatinib.
3) or with ethyl acetate be added drop-wise in the solution that step 1) obtains, separate out crystal under stirring.
4) filter, promptly obtain II type Dasatinib.
Dasatinib polymorph of the present invention is easy to suitability for industrialized production, is a kind of pharmaceutically acceptable, stable Dasatinib new crystal, is suitable for further preparing various formulations, the bioavailability height of preparation finished product.
Description of drawings
Fig. 1 is Dasatinib I type polymorphic form X-RD figure;
Fig. 2 is Dasatinib I type polymorphic form DSC figure;
Fig. 3 is Dasatinib I type polymorphic form TGA figure;
Fig. 4 is Dasatinib II type polymorphic form X-RD figure;
Fig. 5 is Dasatinib II type polymorphic form DSC figure;
Fig. 6 is Dasatinib II type polymorphic form TGA figure;
Fig. 7 is Dasatinib III type polymorphic form X-RD figure;
Fig. 8 is Dasatinib III type polymorphic form DSC figure;
Fig. 9 is Dasatinib III type polymorphic form TGA figure;
Figure 10 is Dasatinib IV type polymorphic form X-RD figure;
Figure 11 is Dasatinib IV type polymorphic form DSC figure;
Figure 12 is Dasatinib IV type polymorphic form TGA figure.
Embodiment
The present invention is further detailed explanation below in conjunction with drawings and Examples:
Embodiment 1
The preparation of II type Dasatinib polymorph
The 5g Dasatinib is joined in the dichloromethane solvent of 25ml, about 2~3 hours of temperature rising reflux is reduced to room temperature, filters, and the filter cake natural air drying obtains the Dasatinib polymorph of 6.3g II type.
Embodiment 2
The preparation of II type Dasatinib polymorph
The 5g Dasatinib is dissolved in the 30ml dimethyl sulfoxide (DMSO), slowly is added drop-wise in the methylene dichloride of 300ml then, drip off after-filtration, the filter cake natural air drying obtains the Dasatinib polymorph of 6.1g II type.
Embodiment 3
The preparation of the Dasatinib of III type
The 3g Dasatinib is dissolved in the 20ml dimethyl sulfoxide (DMSO), slowly is added drop-wise in the isopropyl ether of 180ml then, drip off after-filtration, the filter cake natural air drying obtains the Dasatinib polymorph of 3.5g III type.
Embodiment 4
The preparation of the Dasatinib of III type
The 3g Dasatinib is dissolved in the 90ml dimethyl sulfoxide (DMSO), slowly is added drop-wise in the isopropyl ether of 300ml then, drip off after-filtration, the filter cake natural air drying obtains the Dasatinib polymorph of 3.4g III type.
Embodiment 5
The preparation of the Dasatinib of III type
The 50g Dasatinib is joined in the isopropyl ether of 250ml, about 2~3 hours of temperature rising reflux is reduced to room temperature, filters, and drying under reduced pressure is 4 hours under the filter cake room temperature, obtains the Dasatinib polymorph of 63.2g III type.
Embodiment 6
The preparation of the Dasatinib polymorph of IV type
The 5g Dasatinib is joined to add thermosol among the DMF of 30ml clear, with the speed of per hour the falling 10 ℃ crystallization of slowly lowering the temperature, 0 ℃ of drying under reduced pressure of filter 23 4 hours obtains 5.5g IV type Dasatinib polymorph.
Embodiment 7
The preparation of the Dasatinib polymorph of IV type
The 5ml ethyl acetate slowly is added drop-wise to stirring and crystallizing in the DMF solution of the 3.5ml that contains the 0.5g Dasatinib, filters, drying under reduced pressure is 4 hours under the filter cake room temperature, obtains the Dasatinib polymorph of 0.36g IV type.
Embodiment 8
The preparation of the Dasatinib polymorph of I type
II type Dasatinib polymorph, III type Dasatinib polymorph or IV type Dasatinib Dasatinib polymorph that embodiment 1~7 preparation method is obtained, under 30 ℃, 40 ℃, 70 ℃ conditions dry 2 hours, 4 hours, 8 hours respectively, remove the Dasatinib polymorph that solvent can obtain the I type.
Embodiment 9
The II type Dasatinib polymorph that embodiment 1 is prepared, the III type Dasatinib polymorph that embodiment 3 prepares under 40 ℃ of conditions dry 4 hours, are removed the Dasatinib polymorph that solvent can obtain the I type.
The weight ratio of II type Dasatinib polymorph and III type Dasatinib polymorph is 1: 1.

Claims (22)

1. polymorphic form that is designated as Dasatinib I type.
2. the polymorphic form of Dasatinib I type according to claim 1 is characterized in that, the powder diffraction spectrum of this polymorphic form comprises and is selected from following 2 θ values more than 3 or 3: 7.2 °, and 10.6 °, 12.2 °, 14.5 °, 16.4 °, 20.0 °, 22.8 °, 23.7 ± 0.2 °.
3. the polymorphic form of Dasatinib I type according to claim 1 is characterized in that, dsc is analyzed collection of illustrative plates has the feature endotherm(ic)peak at 285~287 ℃.
4. the polymorphic form of Dasatinib I type according to claim 1 is characterized in that, the thermogravimetric analysis collection of illustrative plates is weightless about below 1%.
5. according to the preparation method of the polymorphic form of each described Dasatinib I type of claim 1~4, it is characterized in that, comprise the steps: the raw material Dasatinib is removed solvent, can obtain the polymorphic form of Dasatinib I type.
6. method according to claim 5 is characterized in that, said raw material Dasatinib is selected from more than one in II type Dasatinib polymorph, III type Dasatinib polymorph or the IV type Dasatinib polymorph.
7. one kind is designated as Dasatinib II type polymorphic form, it is characterized in that, this polymorphic form is a dichloromethane solvent compound crystal formation.
8. Dasatinib II type polymorphic form according to claim 7, it is characterized in that the powder diffraction spectrum of described polymorphic form comprises and is selected from following 2 θ values more than 4 or 4: 5.9 °, 11.8 °, 12.4 °, 14.8 °, 17.7 °, 18.6 °, 21.6 °, 22.9 °, 23.7 °, 25.4 ± 0.2 °.
9. Dasatinib II type polymorphic form according to claim 7 is characterized in that the DSC collection of illustrative plates has the feature endotherm(ic)peak at about 80~160 ℃ and 285~287 ℃.
10. Dasatinib II type polymorphic form according to claim 7 is characterized in that, the TGA collection of illustrative plates shows weightless about 14%.
11. the preparation method according to each described Dasatinib II type polymorphic form of claim 7~10 comprises the steps:
1) the crude product Dasatinib is suspended in the methylene dichloride, 20~40 ℃ were stirred 0.5~1 hour down;
2) filter, the filter cake washed with dichloromethane promptly obtains II type Dasatinib.
3) or with Dasatinib be dissolved in the aqueous organic solvent, obtain Dasatinib solution.
4) this drips of solution is added in the methylene dichloride.
5) filter, promptly obtain II type Dasatinib.
12. method according to claim 11 is characterized in that, described aqueous organic solvent is selected from methyl alcohol, ethanol, 1-propyl alcohol, 2-propyl alcohol, tetrahydrofuran (THF), ethylene glycol, methyl-sulphoxide, N, dinethylformamide and their mixture thereof.
13. one kind is designated as Dasatinib III type polymorphic form, it is characterized in that, this polymorphic form is an isopropyl ether solvate crystal formation.
14. Dasatinib III type polymorphic form according to claim 13 is characterized in that, the powder diffraction spectrum of this polymorphic form comprises and is selected from following 2 θ values more than 4 or 4: 5.9 °, and 11.9 °, 15.0 °, 16.6 °, 21.5 °, 22.9 °, 24.0 °, 24.5 ± 0.2 °.
15. Dasatinib III type polymorphic form according to claim 13 is characterized in that the DSC collection of illustrative plates has the feature endotherm(ic)peak at about 110~160 ℃ and 285~288 ℃.
16. Dasatinib III type polymorphic form according to claim 13 is characterized in that, TGA shows collection of illustrative plates weightless about 13%.
17. prepare the method for each described Dasatinib III type polymorphic form of claim 13~16, comprise the steps:
1) the crude product Dasatinib is suspended in the isopropyl ether, 30~70 ℃ were stirred 0.5~1 hour down.
2) filter, promptly obtain II type Dasatinib.
3) or with Dasatinib be dissolved in the aqueous organic solvent, obtain Dasatinib solution.
4) this drips of solution is added in the isopropyl ether.
5) filter, promptly obtain II type Dasatinib.
The aqueous organic solvent definition is the same.
18. one kind is designated as Dasatinib IV type polymorphic form, it is characterized in that this polymorphic form is N, dinethylformamide solvate crystal formation.
19. Dasatinib IV type polymorphic form according to claim 18, it is characterized in that, the powder diffraction spectrum of this polymorphic form comprises and is selected from following 2 θ values more than 4 or 4: 5.5 °, and 5.9 °, 12.4 °, 14.8 °, 16.5 °, 22.2 °, 22.8 °, 24.8 °, 25.4 ± 0.2 °.
20. Dasatinib IV type polymorphic form according to claim 18 is characterized in that the DSC collection of illustrative plates has the feature endotherm(ic)peak at about 115~139 ℃ and 285~287 ℃.
21. Dasatinib IV type polymorphic form according to claim 18 is characterized in that, TGA shows collection of illustrative plates weightless about 8.67%.
22. the preparation method of each described Dasatinib III type polymorphic form of claim 18~21 comprises the steps:
1) the crude product Dasatinib is suspended in N, in the dinethylformamide, 40~90 ℃ were stirred 0.5~1 hour down.
2) with the speed of per hour the falling 10 ℃ crystallization of slowly lowering the temperature.Filter, promptly obtain II type Dasatinib.
3) or with ethyl acetate be added drop-wise in the solution that step 1) obtains, separate out crystal under stirring.
4) filter, promptly obtain II type Dasatinib.
CN2009101969878A 2009-10-10 2009-10-10 Dasatinib polymorph and preparation method thereof Pending CN102040596A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009101969878A CN102040596A (en) 2009-10-10 2009-10-10 Dasatinib polymorph and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101969878A CN102040596A (en) 2009-10-10 2009-10-10 Dasatinib polymorph and preparation method thereof

Publications (1)

Publication Number Publication Date
CN102040596A true CN102040596A (en) 2011-05-04

Family

ID=43907162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009101969878A Pending CN102040596A (en) 2009-10-10 2009-10-10 Dasatinib polymorph and preparation method thereof

Country Status (1)

Country Link
CN (1) CN102040596A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102030745A (en) * 2010-11-26 2011-04-27 江苏先声药物研究有限公司 Dasatinib solvate and preparation method thereof
CN102250084A (en) * 2010-02-08 2011-11-23 南京卡文迪许生物工程技术有限公司 Dasatinib polymorphic substance as well as preparation method and pharmaceutical composition thereof
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 Novel polymorphs of dasatinib, and preparation method thereof
CN103664929A (en) * 2012-08-30 2014-03-26 石药集团中奇制药技术(石家庄)有限公司 Dasatinib polycrystalline form medicament and preparation method thereof
CN103819469A (en) * 2012-11-16 2014-05-28 重庆医药工业研究院有限责任公司 Crystal form of dasatinib and preparation method for crystal form of dasatinib
CN104130251A (en) * 2011-07-29 2014-11-05 江苏奥赛康药业股份有限公司 Dasatinib compound and preparation method thereof
CN104997737A (en) * 2015-08-05 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 Composition dry suspension of medicine dasatinib tablet for treating leukemia
CN105030778A (en) * 2015-09-22 2015-11-11 青岛华之草医药科技有限公司 Dasatinib composition granule serving as medicine for treating leukemia
CN105055327A (en) * 2015-07-30 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 Dasatinib composite granules capable of treating leukaemia
CN105055367A (en) * 2015-08-18 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 SprycelTM composition capsule medicine for treating leukemia
CN105130979A (en) * 2015-08-10 2015-12-09 青岛蓝盛洋医药生物科技有限责任公司 Drug dasatinib compound for treatment of leukemia and preparation method thereof
CN105237529A (en) * 2015-10-29 2016-01-13 四川协力制药有限公司 Refining method for high-purity anhydrous dasatinib
CN105408329A (en) * 2013-07-25 2016-03-16 巴斯夫欧洲公司 Salts of dasatinib in crystalline form
WO2017134615A1 (en) * 2016-02-03 2017-08-10 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250084A (en) * 2010-02-08 2011-11-23 南京卡文迪许生物工程技术有限公司 Dasatinib polymorphic substance as well as preparation method and pharmaceutical composition thereof
CN102030745A (en) * 2010-11-26 2011-04-27 江苏先声药物研究有限公司 Dasatinib solvate and preparation method thereof
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 Novel polymorphs of dasatinib, and preparation method thereof
CN104130251A (en) * 2011-07-29 2014-11-05 江苏奥赛康药业股份有限公司 Dasatinib compound and preparation method thereof
CN103664929A (en) * 2012-08-30 2014-03-26 石药集团中奇制药技术(石家庄)有限公司 Dasatinib polycrystalline form medicament and preparation method thereof
CN103664929B (en) * 2012-08-30 2016-08-03 石药集团中奇制药技术(石家庄)有限公司 Dasatinib polycrystalline form medicament and preparation method
CN103819469A (en) * 2012-11-16 2014-05-28 重庆医药工业研究院有限责任公司 Crystal form of dasatinib and preparation method for crystal form of dasatinib
CN105408329A (en) * 2013-07-25 2016-03-16 巴斯夫欧洲公司 Salts of dasatinib in crystalline form
CN105055327A (en) * 2015-07-30 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 Dasatinib composite granules capable of treating leukaemia
CN104997737A (en) * 2015-08-05 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 Composition dry suspension of medicine dasatinib tablet for treating leukemia
CN105130979A (en) * 2015-08-10 2015-12-09 青岛蓝盛洋医药生物科技有限责任公司 Drug dasatinib compound for treatment of leukemia and preparation method thereof
CN105055367A (en) * 2015-08-18 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 SprycelTM composition capsule medicine for treating leukemia
CN105030778A (en) * 2015-09-22 2015-11-11 青岛华之草医药科技有限公司 Dasatinib composition granule serving as medicine for treating leukemia
CN105237529A (en) * 2015-10-29 2016-01-13 四川协力制药有限公司 Refining method for high-purity anhydrous dasatinib
WO2017134615A1 (en) * 2016-02-03 2017-08-10 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation
US10464933B2 (en) 2016-02-03 2019-11-05 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation

Similar Documents

Publication Publication Date Title
CN102040596A (en) Dasatinib polymorph and preparation method thereof
CN103930419B (en) The brilliant type of Azilsartan and its preparation method
KR101019451B1 (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form ?
CN103974949B (en) A kind of I type crystallization of 2-maleate of tyrosine kinase inhibitor and preparation method
JP2008509953A (en) 4-[[(7R) -8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl] amino] -3-methoxy-N- ( 1-methyl-4-piperidinyl) benzamide hydrates and polymorphs, processes for their preparation and their use as drugs
KR20170057441A (en) Crystal Form of Bisulfate of JAK Inhibitor and Preparation Method Therefor
EP2651952A2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
US10053407B2 (en) Crystalline cannabidivarin
US20070021444A1 (en) Valacyclovir polymorphs and a process for the preparation thereof
KR20170078710A (en) Crystal Form of JAK Kinase inhibitor Bisulfate and a preparation method therefor
CN105764508A (en) Crystalline forms of GRAPIPRANT
JP6511083B2 (en) Crystal of pyrrole derivative
CN102911075A (en) New crystal form I of agomelatine sulfate and preparation method thereof
EP2494971B1 (en) Gambogic acid derivatives, preparative methods and uses thereof
CN100390172C (en) Methane sulfonic acid dolasetron crystallographic form and its preparation method
WO2019127294A1 (en) Ticagrelor purification method
CN102321141B (en) Amorphous substance of 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregn-4,9-diene-3,20-diketone and preparation method thereof
EP2960225A1 (en) New 3,3',5,5'-tetraisopropyl-4,4'-diphenol crystal form and preparation method thereof
CN104402815B (en) Control method of piperaquine phosphate impurity
CN102351784B (en) Benidipine hydrochloride crystal form and application thereof
JP6072908B2 (en) Deuterated ω-dimethylurea or polymorph of its salt
CN105037341A (en) Azilsartan alcohol ammonium crystal form and preparation method thereof
CN108349903B (en) TTP488 addition salt, crystal form, preparation method and pharmaceutical composition thereof
CN108530365B (en) 1, 4-naphthoquinone/anthraquinone imidazole derivative and preparation and application thereof
CN103539683A (en) Novel crystal form of medicament for treating scleredema and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110504